Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-Induced Dyskinesias in Advanced Parkinson's Disease
The study is designed to measure the efficacy and safety of levetiracetam on levodopa-induced dyskinesias in late-stage Parkinson's disease. The patients are planned to be treated with levetiracetam (up to 2000 mg per day) or placebo for 13 weeks. Efficacy measure is the modified AIMS.
Agency:
Dresden University of Technology
Phase:
Phase IV Study Design:
Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Condition:
Parkinson's Disease
Intervention type:
Drug
Intervention Name:
levetiracetam
Information Retrieved from Source:
Tuesday, 10 April 2007